CME Corner

This activity has expired. CME/CE credit is no longer available and the following content may not be available or may not be up-to-date. For a list of current activities that offer CME/CE credit, click here.

Program Detail

Release Date: May-03-10
Credit Expiration Date: May-03-11


Patrick Wood, MD
Pacific Rheumatology Associates
Renton, WA

Credit Hours



Clinical Case Challenge (Online)

Program Description

Fibromyalgia is a chronic disorder characterized by widespread, generalized, muscular pain, affecting mostly women between the ages of 20 and 55. Although fibromyalgia is highly prevalent, it remains poorly understood by primary care providers. Fibromyalgia symptoms can resemble those of many other diseases, and accurate diagnosis and effective treatment often elude affected patients for years. Diagnosing and managing this disorder is a complex process for both providers and patients because definitive, objective testing does not yet exist, and treatment can involve an individualized multimodal mix of nonpharmacologic and pharmacotherapeutic regimens.

The comorbidities associated with fibromyalgia further complicate the diagnosis and management of this condition, so primary care providers must know how to recognize these comorbidities in order to properly manage patients. Primary care clinicians play a critical role in educating and guiding patients through their illnesses. Becoming more familiar with fibromyalgia and its related conditions will help clinicians and their patients develop an integrative approach to symptom management.

Target Audience

This educational activity is designed to meet the needs of primary care physicians, physician assistants, nurse practitioners, and nurses interested in the treatment of patients with fibromyalgia.

Learning Objectives

Upon completion of this educational activity, the participant should be able to:

  1. Discuss diagnostic criteria for fibromyalgia, according to established guidelines
  2. Describe common comorbidities associated with fibromyalgia
  3. Evaluate the role of pharmacologic and nonpharmacologic treatments for patients with fibromyalgia


It is the policy of Temple University School of Medicine to ensure balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. All faculty planning committee members participating in any Temple University sponsored programs are expected to disclose to the program audience ANY real or apparent conflict(s) of interest that may have a direct bearing on the subject matter of the continuing education program. This pertains to relationships with pharmaceutical companies, biomedical device manufacturers, or other corporations whose products or services are related to the subject matter of the presentation topic. The intent of this policy is that any potential conflict should be identified openly so that the participants may form their own judgments about the presentation with the full disclosure of the facts.

Patrick Wood, MD, has no relevant financial relationships to disclose.

Activity planners and reviewers have no relevant financial relationships to disclose.

Credit Statements

Accreditation Statement: Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for physicians.

Certification Statement: Temple University School of Medicine designates this educational activity for a maximum of 1 AMA PRA Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Commercial Support Statements

This activity is supported by an educational grant from Pfizer Inc.

Certificate Fee



Presented by Temple University School of Medicine, the National Fibromyalgia Association, and Medical Communications Media, Inc.

The opinions expressed in these educational activities are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, Temple University School of Medicine, the National Fibromyalgia Association, or Pfizer Inc. Any medications, diagnostic procedures, or treatments discussed by the program presenters should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.

By clicking START PROGRAM I acknowledge that I have read the CME/CE information above.

Main Menu